nach oben

Erschienen in:

06.10.2021 | Multiple Sklerose | Zertifizierte Fortbildung

Neuromyelitis-optica-Spektrum-Erkrankung

NMOSD - vom ersten Schub zur optimalen Behandlung

verfasst von: PD Dr. med. Joachim Havla, Prof. Dr. med. Tania Kümpfel

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Auszug

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) zu erkennen und korrekt einzuordnen ist essenziell für die Behandlung. In diesem Übersichtsartikel werden am Beispiel der Optikusneuritis das Vorgehen im Rahmen der Diagnosestellung und die aktuellen Therapiekonzepte für die NMOSD dargelegt. …

Bennett JL. Optic Neuritis. Continuum (Minneap Minn) 2019;25:1236-64

Pache F, Wildemann B, Paul F, Jarius S. [Neuromyelitis optica]. Fortschr Neurol Psychiatr 2017;85:e1

Jarius S, Wildemann B. [Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. A brief review]. Nervenarzt 2021;92:317-33

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15

Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:555-6

Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(Pt 11): 2059-69

Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 2017; 264:453-66

Trebst C, Berthele A, Jarius S, Kumpfel T, Schippling S, Wildemann B et al. [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group]. Nervenarzt 2011;82:768-77

10.

Oertel FC, Outteryck O, Knier B, Zimmermann H, Borisow N, Bellmann-Strobl J et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation 2019;16:154

11.

Havla J, Pakeerathan T, Schwake C, Bennett JL, Kleiter I, Felipe-Rucian A et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation 2021;18:121

12.

Reindl M. Clinical course of MOG antibody-associated recurrent demyelinating diseases. J Neurol Neurosurg Psychiatry 2018;89:118

13.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]. Nervenarzt 2018;89:1388-99

14.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280

15.

Jarius S, Lechner C, Wendel EM, Baumann M, Breu M, Schimmel M et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. J Neuroinflammation 2020; 17:262

16.

Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 2020;17:261

17.

Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflamm 2016;3:e231

18.

Pache F, Wildemann B, Paul F, Jarius S. [Neuromyelitis optica]. Fortschr Neurol Psychiatr 2017;85:100-14

19.

Outteryck O, Lopes R, Drumez E, Labreuche J, Lannoy J, Hadhoum N et al. Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology 2020;95:e733-e44

20.

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Multiple Sclerosis Journal 2015;21:678-88

21.

Oertel FC, Zimmermann H, Paul F, Brandt AU. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA J 2018;9:21-33

22.

Havla J, Kumpfel T, Schinner R, Spadaro M, Schuh E, Meinl E et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 2017;264:139-51

23.

Motamedi S, Oertel FC, Yadav SK, Kadas EM, Weise M, Havla J et al. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology & Neuroinflammation 2020;7:e805

24.

Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S et al. Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. J Neurol Neurosurg Psychiatry 2020;92:377-83

25.

Oertel FC, Havla J, Roca-Fernandez A, Lizak N, Zimmermann H, Motamedi S et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 2018;89:1259-65

26.

Aktas O, Kumpfel T. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]. Nervenarzt 2021;92:307-16

27.

Ayzenberg I, Kleiter I. [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease]. Nervenarzt 2021;92:334-48

28.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

29.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017;88:639-47

30.

Huang Q, Wang J, Zhou Y, Yang H, Wang Z, Yan Z et al. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China. Front Immunol 2018;9:2066

31.

Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep 2020;10:16727

32.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020;19:298-306

33.

Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020;19: 391-401

34.

Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-7

35.

Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45

36.

Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016;263:25-9

37.

Ayzenberg I, Schollhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 2016;263:575-82

38.

Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-5

39.

Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 2017;23:1297-300

40.

Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19:402-12

41.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352-63

42.

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019;381:614-25

43.

Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019;381:2114-24

44.

Krankheitsbezogenes Kompetenznetz Multiple Sklerose e. V.. Qualitätshandbuch MS / NMOSD. Empfehlungen zur Therapie der Multiplen Sklerose / Neuromyelitis-optica-Spektrum-Erkrankungen für Ärzte. Ausgabe Dezember 2020:1-400. https://www.kompetenznetz-multiplesklerose.de/fachinformationen/qualitaetshandbuch/ [Zugriff 11.7.2021]

Titel: Neuromyelitis-optica-Spektrum-Erkrankung
NMOSD - vom ersten Schub zur optimalen Behandlung
verfasst von: PD Dr. med. Joachim Havla
Prof. Dr. med. Tania Kümpfel
Publikationsdatum: 06.10.2021
Verlag: Springer Medizin
Schlagwörter: Multiple Sklerose
Optikusneuritis
Neuromyelitis-optica-Spektrum-Erkrankung
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 5/2021
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-021-4735-1

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Schlaganfall oder nicht? - Im Zweifelsfall lysieren

Aufräumen mit Mythen und Vorurteilen bei ADHS – ein "must read"

Beeinflussen Abhängigkeitserkrankungen das Outcome bei ADHS?

Warten auf die ADHS-Therapie – die Zeit mit Chatbots überbrücken?

Cannabispräparat als Add-on-Therapie bei Morbus Parkinson

Die Neurodegeneration an den Augen ablesen